APPENDIX 24: ECONOMIC EVIDENCE PROFILE

Clinical /economic question: pharmacological and psychological interventions for adults with social anxiety 2

Abbreviations

CBT	cognitive behavioural therapy
CT	cognitive therapy
EQ-5D	European Quality of Life – 5 Dimensions
GDG	Guideline Development Group
NHS	National Health Service
PSS	personal social services
QALY	quality adjusted life year
UK	United Kingdom

Clinical /economic question: pharmacological and psychological interventions for adults with social anxiety

Study and country	Limitations	Applica-bility	Incremental cost versus waitlist (£)[1]		Incremental QALYs versus waitlist		Net monetary benefit		Uncertainty
Guideline economic analysis, UK	Minor limitations[2]	Directly applicable[3]	CT (Clark and Wells) standard	1,448	CT (Clark and Wells) standard	0.380	CT (Clark and Wells) standard	69,194	*Probabilistic analysis*: probability of CT (Clark and Wells) standard having highest net monetary benefit 69%
			CBT individual	1,017	CBT individual	0.269	CBT individual	67,392	
			CBT (Heimberg) individual	1,158	CBT (Heimberg) individual	0.218	Phenelzine	67,165	
			Phenelzine	-29	Phenelzine	0.205	Unsupported self-help book	66,400	
			CT (Clark and Wells) shortened sessions	1,252	CT (Clark & Wells) shortened sessions	0.202	CBT (Heimberg) individual	66,246	
							Supported self-help book	66,243	
			Supported self-help internet	581	Supported self-help internet	0.174	Supported self-help internet	65,932	
			CBT group	770	CBT group	0.168	Paroxetine	65,893	
			Supported self-help book	136	Supported self-help book	0.167	CT (Clark and Wells) shortened sessions	65,821	
			Unsupported self-help book	-87	Unsupported self-help book	0.164			
			Exposure	781	Exposure	0.161	CBT group	65,625	*One-way deterministic analysis*: results not sensitive to alternative unit costs and utility values
			CBT (Heimberg) group	794	CBT (Heimberg) group	0.154	Venlafaxine	65,571	
			Paroxetine	-40	Paroxetine	0.141	Fluvoxamine	65,540	
			Venlafaxine	123	Venlafaxine	0.133	Sertraline	65,524	
			Fluvoxamine	58	Fluvoxamine	0.128	Exposure	65,480	
			Sertraline	-19	Sertraline	0.123	CBT (Heimberg) group	65,319	
			Unsupported self-help internet	449	Unsupported self-help internet	0.117	Fluoxetine	65,285	
			Escitalopram	92	Escitalopram	0.115	Escitalopram	65,243	
			Fluoxetine	-6	Fluoxetine	0.112	Citalopram	65,175	
			Psychodynamic psychotherapy	1,756	Psychodynamic psychotherapy	0.107	Mirtazapine	65,046	
			Citalopram	1	Citalopram	0.107	Unsupported self-help internet	64,939	
			Mirtazapine	12	Mirtazapine	0.101	Moclobemide	64,603	
			Moclobemide	129	Moclobemide	0.084	Pregabalin	64,402	
			Pregabalin	298	Pregabalin	0.083	Mindfulness training	63,776	
			Interpersonal psychotherapy	1,278	Interpersonal psychotherapy	0.066	Placebo	63,631	
			Mindfulness training	410	Mindfulness training	0.057	Psychodynamic psychotherapy	63,432	
			Placebo	107	Placebo	0.035	Interpersonal psychotherapy	63,074	
			Supportive therapy	1,227	Supportive therapy	0.033	Wait list	63,038	
			Wait list	0	Wait list	0.000	Supportive therapy	62,480	

1. Costs uplifted to 2012 UK pounds using the UK Hospital and Community Health Service inflation index.
2. Efficacy data taken from guideline network meta-analysis; side effects of drugs (including disutilities and management costs) not considered; resource use based on published data and GDG expert opinion; national unit costs used; probabilistic and deterministic sensitivity analysis conducted.
3. NHS and PSS perspective, QALYs based on EQ-5D UK tariff, annual discount rate 3.5%.